Societal preference values for advanced melanoma health states in the United Kingdom and Australia.

<bold>Background: </bold>No studies measure preference-based utilities in advanced melanoma that capture both intended clinical response and unintended toxicities associated with treatment.<bold>Methods: </bold>Using standard gamble, utilities were elicited from 140 respondents in the United Kingdom and Australia for 13 health states.<bold>Results: </bold>Preferences decreased with reduced treatment responsiveness and with increasing toxicity.<bold>Conclusions: </bold>These general population utilities can be incorporated into treatment-specific cost-effectiveness evaluations. [ABSTRACT FROM AUTHOR]